Who we are

Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.

At a glance

Our company by the numbers

50,129,284

Patients with neurodegenerative diseases

42

Employees living and working across the world

58%

Improvement in memory functions for clinical trial patients

2016

Year we were officially founded

The Founders

Ed boyden
Ed Boyden

Founder

Li huei tsai
Li-Huei Tsai

Founder

Meet the team

You?

Brent Vaughan
Brent Vaughan

Chief Executive Officer

Tom Megerian Sq
Tom Megerian

Chief Medical Officer

Mihaly Hajos
Mihály Hajós

Chief Scientific Officer

Everett Crosland
Everett Crosland

Chief Commercial Officer

Zach Malchano
Zach Malchano

Chief R&D Officer, President

Divya
Divya Cohen

Vice President, Product

Holder
Sean Gregory

Vice President, Health Economics & Market Access

Celine Houser
Celine Houser

Vice President, Clinical Operations

Kim Kwan
Kim Kwan

Vice President, Research & Development

Jennifer Newberger
Jennifer Newberger

Vice President, Regulatory & Compliance

Kimberly ha
Kimberly Ha

PR & Investor Relations

Recognized and proud

Aetion Logo 1
DAC Logo 1 2
DIME Logo 1
Norman Felix institute
Providence HP logo 2
Latest news and updates

Stay up to date

Designimage

Dec 1, 2022

Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients
Fierceimage

Aug 3, 2022

Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
Economist77

May 2, 2022

Some health apps are able not just to diagnose diseases, but also to treat them
Article placeholder black

Apr 13, 2022

Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis